Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Histidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 3/20 | 0.57 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.93 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.93 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | APEX1 | P27695 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histidine SCHEMBL31618930 | 1.00 | CYP3A4 (0.93) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| Histidine SCHEMBL1705391 | 1.00 | CYP3A4 (0.93) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| Histidine SCHEMBL29250215 | 1.00 | CYP3A4 (0.93) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| D-Histidine SCHEMBL3639231 | 1.00 | CYP3A4 (0.93) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| Histidine SCHEMBL3644995 | 1.00 | CYP3A4 (0.93) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| Histidine SCHEMBL209484 | 0.98 | CYP3A4 (0.97) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| D-Histidine SCHEMBL8002459 | 0.98 | CYP3A4 (0.97) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| Histidine SCHEMBL5134199 | 0.98 | CYP3A4 (0.97) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| Histidine SCHEMBL3154317 | 0.98 | CYP3A4 (0.97) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 | |
| Histidine SCHEMBL16893960 | 0.98 | CYP3A4 (0.97) | CYP3A4SLC7A5ALDH1A1HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2827 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102378-A1 | CELL CULTURE ADDITIVE AND USES THEREOF | NANJING PROBIO BIOTECH CO., LTD. (CN) | 2026-05-15 | — | — | WO | claimed |
| EP-4423126-B1 | METHODS OF TREATING CROHN'S DISEASE WITH ANTI-IL23 SPECIFIC ANTIBODY | JANSSEN BIOTECH INC (US) | 2026-05-06 | — | — | EP | claimed |
| US-20260116999-A1 | USES OF OMALIZUMAB | NOVARTIS AG (CH) | 2026-04-30 | — | — | US | claimed |
| EP-4733320-A2 | METHODS OF TREATING CROHN'S DISEASE WITH ANTI-IL23 SPECIFIC ANTIBODY | Janssen Biotech, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260103510-A1 | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody | JANSSEN BIOTECH INC (US) | 2026-04-16 | — | — | US | claimed |
| EP-4724475-A2 | CLEC9A-BASED CHIMERIC PROTEIN FORMULATIONS | Orionis Biosciences, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4714504-A2 | SAFE AND EFFECTIVE METHOD OF TREATING PSORIASIS WITH ANTI-IL23 SPECIFIC ANTIBODY | Janssen Biotech, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| US-20260069707-A1 | COMBINATION THERAPY WITH ANTIBODY-DRUG CONJUGATES AND HYALURONIDASES | HALOZYME, INC. (US) | 2026-03-12 | — | — | US | claimed |
| US-20260047992-A1 | COSMETIC COMPOSITION COMPRISING CELL CULTURE MEDIUM AND ALBUMIN, AND USE THEREOF | COSMAX, INC. (KR) | 2026-02-19 | — | — | US | claimed |
| EP-4683947-A1 | NEW USES OF OMALIZUMAB | Novartis AG (CH) | 2026-01-28 | — | — | EP | claimed |
| EP-1578449-A2 | COMPOSITIONS OF BENZOQUINOLIZINE CARBOXYLIC ACID ANTIBIOTIC DRUGS | Wockhardt Limited (IN) | 2005-09-28 | — | — | EP | claimed |
| US-20040176321-A1 | Compositions of benzoquinolizine carboxylic acid antibiotic drugs | WOCKHARDT LIMITED | 2004-09-09 | — | — | US | claimed |
| WO-2004058303-A2 | COMPOSITIONS OF BENZOQUINOLIZINE CARBOXYLIC ACID ANTIBIOTIC DRUGS | WOCKHARDT LIMITED (IN) | 2004-07-15 | — | — | WO | claimed |
| WO-2002022120-A1 | PAIN RELIEVER AND METHOD OF USE | MEDICAL MERCHANDISING, INC. (US) | 2002-03-21 | — | — | WO | claimed |
| US-6197823-B1 | Pain reliever and method of use | MEDICAL MERCHANDISING, INC. | 2001-03-06 | — | — | US | claimed |
| US-5821074-A | ANALYZING FOR LEAD | ABBOTT LABORATORIES (US) | 1998-10-13 | — | — | US | claimed |
| US-5597702-A | ENZYME INHIBITOR | ABBOTT LABORATORIES (US) | 1997-01-28 | — | — | US | claimed |
| EP-0736181-A1 | AUTOMATED LEAD ASSAY | Abbott Laboratories (US) | 1996-10-09 | — | — | EP | claimed |
| WO-1995017679-A1 | AUTOMATED LEAD ASSAY | ABBOTT LABORATORIES (US) | 1995-06-29 | — | — | WO | claimed |
| US-5252322-A | Skin tanning compositions containing imidazoles | THE GILLETTE COMPANY (US) | 1993-10-12 | — | — | US | claimed |